Comparison 4. Alternative lipid emulsion (LE) vs another alternative‐LE (see Appendix 3).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Days to regain birth weight	1	59	Mean Difference (IV, Fixed, 95% CI)	‐2.0 [‐5.73, 1.73]
1.1 MS‐LE vs OS‐LE	1	59	Mean Difference (IV, Fixed, 95% CI)	‐2.0 [‐5.73, 1.73]
2 Growth rate (g/kg/day)	1	59	Mean Difference (IV, Fixed, 95% CI)	‐1.33 [‐7.36, 4.70]
2.1 MS‐LE vs OS‐LE	1	59	Mean Difference (IV, Fixed, 95% CI)	‐1.33 [‐7.36, 4.70]
3 Parenteral nutrition‐associated liver disease (PNALD)/cholestasis (conjugated bilirubin ≥ 2 mg/dL)	1	59	Risk Ratio (M‐H, Fixed, 95% CI)	2.90 [0.12, 68.50]
3.1 MS‐LE vs OS‐LE	1	59	Risk Ratio (M‐H, Fixed, 95% CI)	2.90 [0.12, 68.50]
4 PNALD/cholestasis (any definition)	1	59	Risk Ratio (M‐H, Fixed, 95% CI)	2.90 [0.12, 68.50]
4.1 MS‐LE vs OS‐LE	1	59	Risk Ratio (M‐H, Fixed, 95% CI)	2.90 [0.12, 68.50]
5 Death before discharge	1	60	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
5.1 MS‐LE vs OS‐LE	1	60	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
6 Chronic lung disease (oxygen requirement at 36 weeks)	1	59	Risk Ratio (M‐H, Fixed, 95% CI)	0.77 [0.23, 2.60]
6.1 MS‐LE vs OS‐LE	1	59	Risk Ratio (M‐H, Fixed, 95% CI)	0.77 [0.23, 2.60]
7 Any sepsis (clinical or culture positive (or both))	1	59	Risk Ratio (M‐H, Fixed, 95% CI)	1.93 [0.65, 5.73]
7.1 MS‐LE vs OS‐LE	1	59	Risk Ratio (M‐H, Fixed, 95% CI)	1.93 [0.65, 5.73]
8 Necrotising enterocolitis (≥ stage 2)	1	59	Risk Ratio (M‐H, Fixed, 95% CI)	1.93 [0.19, 20.18]
8.1 MS‐LE vs OS‐LE	1	59	Risk Ratio (M‐H, Fixed, 95% CI)	1.93 [0.19, 20.18]
9 Any patent ductus arteriosus	1	59	Risk Ratio (M‐H, Fixed, 95% CI)	1.10 [0.68, 1.75]
9.1 MS‐LE vs OS‐LE	1	59	Risk Ratio (M‐H, Fixed, 95% CI)	1.10 [0.68, 1.75]
10 Conjugated bilirubin levels (µmol/L)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
10.1 MS‐LE vs OS‐LE	1	59	Mean Difference (IV, Fixed, 95% CI)	‐2.91 [‐6.87, 1.05]